Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes.
Anaplastic large-cell lymphoma
Angioimmunoblastic T cell lymphoma
Peripheral T cell lymphoma
Relapsed disease
Therapy
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
16 04 2020
16 04 2020
Historique:
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
19
8
2021
Statut:
epublish
Résumé
Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas with inferior prognosis compared with their B cell counterparts characterized by frequent relapses, resulting in a median 5-year survival of approximately 30%. Their diverse clinicopathologic features challenge existing treatment paradigms that treat all patients uniformly. Here we review recent advances in the treatment of these diseases. While current treatment still relies largely on combination chemotherapy, the introduction of more effective novel and targeted therapies has improved outcomes in certain subtypes. Increasing understanding of the underlying biology of PTCL has prompted further subclassification by genetic and molecular subgroups. Overall, the most significant advances in PTCL management have resulted from improved understanding and classification of the biology of PTCL. Ongoing development of subtype-specific targeted therapies will be essential to improve long-term outcomes of patients with these diseases.
Identifiants
pubmed: 32297075
doi: 10.1007/s11912-020-00902-1
pii: 10.1007/s11912-020-00902-1
doi:
Substances chimiques
Ki-1 Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Références
Ann Oncol. 2014 Nov;25(11):2211-2217
pubmed: 25193992
Blood Adv. 2017 Oct 27;1(24):2138-2146
pubmed: 29296861
Eur J Haematol. 2007 Apr;78(4):290-6
pubmed: 17378891
Int J Hematol. 2014 Mar;99(3):219-26
pubmed: 24481943
Blood. 2018 Jul 19;132(3):245-253
pubmed: 29699989
Blood. 2015 Jul 2;126(1):17-25
pubmed: 25869285
Blood Rev. 2016 Mar;30(2):89-100
pubmed: 26319391
Ann Oncol. 2008 May;19(5):958-63
pubmed: 18303032
J Clin Oncol. 2017 Dec 20;35(36):4019-4026
pubmed: 29072976
Haematologica. 2018 Jul;103(7):1191-1197
pubmed: 29599200
Blood. 2018 Jan 25;131(4):397-407
pubmed: 29141948
Cancer Cell. 2018 Feb 12;33(2):259-273.e7
pubmed: 29398449
Ann Hematol. 2018 Jul;97(7):1241-1250
pubmed: 29549411
Haematologica. 2020 Jun;105(6):1582-1592
pubmed: 31488561
Blood. 2010 Nov 4;116(18):3418-25
pubmed: 20660290
Blood. 2018 Feb 22;131(8):888-898
pubmed: 29233821
J Clin Oncol. 2014 Apr 10;32(11):1157-63
pubmed: 24616310
Cancer. 2015 Mar 1;121(5):716-23
pubmed: 25355245
Lancet Haematol. 2015 Aug;2(8):e326-33
pubmed: 26688485
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Blood. 2014 Sep 4;124(10):1570-7
pubmed: 25006130
Cancer. 2019 May 1;125(9):1507-1517
pubmed: 30694529
Hematology. 2016 Oct;21(9):536-41
pubmed: 27077778
Blood. 2019 Oct 24;134(17):1395-1405
pubmed: 31471376
J Clin Oncol. 2011 Mar 20;29(9):1182-9
pubmed: 21245435
J Clin Invest. 2017 Sep 1;127(9):3462-3471
pubmed: 28805662
Ann Oncol. 2017 Sep 01;28(9):2169-2178
pubmed: 28633365
Blood. 2014 May 15;123(20):3095-100
pubmed: 24652992
Blood. 2004 Aug 1;104(3):626-33
pubmed: 14982884
Eur J Haematol. 2007 Jul;79(1):32-8
pubmed: 17598836
Blood. 2017 Dec 21;130(25):2709-2717
pubmed: 28974506
Blood. 2003 Dec 15;102(13):4284-9
pubmed: 12920037
Cancer. 2017 Apr 1;123(7):1174-1183
pubmed: 27911989
J Clin Oncol. 2012 Feb 20;30(6):631-6
pubmed: 22271479
J Hematol Oncol. 2016 Mar 10;9:22
pubmed: 26965915
Lancet Haematol. 2018 May;5(5):e190-e200
pubmed: 29703335
Blood. 2004 Aug 1;104(3):634-41
pubmed: 15016643
Eur J Cancer. 2012 Nov;48(17):3223-31
pubmed: 22770877
N Engl J Med. 2018 May 17;378(20):1947-1948
pubmed: 29768155
Br J Haematol. 2016 Feb;172(4):535-44
pubmed: 26627450
Oncotarget. 2017 Dec 21;9(4):4737-4757
pubmed: 29435138
J Hematol Oncol. 2016 Apr 12;9:38
pubmed: 27071522
Lancet Haematol. 2015 Apr;2(4):e160-5
pubmed: 26687958
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
J Hematol Oncol. 2019 Jan 10;12(1):6
pubmed: 30630534
Blood. 2018 Nov 22;132(21):2305-2309
pubmed: 30279227
Crit Rev Oncol Hematol. 2016 Mar;99:214-27
pubmed: 26811013
Cancer. 2014 Jul 1;120(13):1993-9
pubmed: 24706502
J Clin Oncol. 2013 Jan 1;31(1):104-10
pubmed: 23109692
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Ann Hematol. 2019 Aug;98(8):1961-1972
pubmed: 31065733
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
J Clin Oncol. 2013 Aug 20;31(24):3019-25
pubmed: 23857971
Blood Cancer J. 2016 Jul 29;6(7):e452
pubmed: 27471868
J Clin Oncol. 2012 Sep 1;30(25):3093-9
pubmed: 22851556
Am J Surg Pathol. 2007 Jul;31(7):1077-88
pubmed: 17592275
J Clin Oncol. 2016 Mar 20;34(9):963-71
pubmed: 26962200
Ann Oncol. 2018 Mar 1;29(3):715-723
pubmed: 29253087
N Engl J Med. 2005 Mar 24;352(12):1197-205
pubmed: 15788496
Am J Hematol. 2016 Jul;91(7):672-6
pubmed: 27012928
Leukemia. 2006 Sep;20(9):1533-8
pubmed: 16871285
J Clin Oncol. 2015 Aug 10;33(23):2492-9
pubmed: 26101246
J Clin Oncol. 2019 Mar 10;37(8):613-623
pubmed: 30707661
Ann Oncol. 2016 Apr;27(4):712-8
pubmed: 26861608
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3
pubmed: 31029646
Br J Haematol. 2017 Sep;178(5):772-780
pubmed: 28597542
Oncotarget. 2017 Mar 14;8(11):17763-17770
pubmed: 28148900
Leuk Lymphoma. 2019 Dec;60(12):2927-2930
pubmed: 31119966
Leukemia. 2019 Dec;33(12):2867-2883
pubmed: 31092896
J Hematol Oncol. 2014 Mar 19;7:24
pubmed: 24642247
J Clin Oncol. 2013 Jun 1;31(16):1970-6
pubmed: 23610113